724 related articles for article (PubMed ID: 28276855)
1. The safety of vedolizumab for the treatment of ulcerative colitis.
Novak G; Hindryckx P; Khanna R; Jairath V; Feagan BG
Expert Opin Drug Saf; 2017 Apr; 16(4):501-507. PubMed ID: 28276855
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
McLean LP; Cross RK
Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
[TBL] [Abstract][Full Text] [Related]
3. Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis.
Battat R; Ma C; Jairath V; Khanna R; Feagan BG
Drug Saf; 2019 May; 42(5):617-632. PubMed ID: 30830573
[TBL] [Abstract][Full Text] [Related]
4. A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis.
Tsai HH; Black C
Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):679-683. PubMed ID: 27726457
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists.
Feagan BG; Rubin DT; Danese S; Vermeire S; Abhyankar B; Sankoh S; James A; Smyth M
Clin Gastroenterol Hepatol; 2017 Feb; 15(2):229-239.e5. PubMed ID: 27639327
[TBL] [Abstract][Full Text] [Related]
6. The safety of vedolizumab for ulcerative colitis and Crohn's disease.
Colombel JF; Sands BE; Rutgeerts P; Sandborn W; Danese S; D'Haens G; Panaccione R; Loftus EV; Sankoh S; Fox I; Parikh A; Milch C; Abhyankar B; Feagan BG
Gut; 2017 May; 66(5):839-851. PubMed ID: 26893500
[TBL] [Abstract][Full Text] [Related]
7. Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis.
Hagan M; Cross RK
Expert Opin Drug Saf; 2015; 14(9):1473-9. PubMed ID: 26138111
[TBL] [Abstract][Full Text] [Related]
8. Vedolizumab for the treatment of ulcerative colitis.
Stallmach A; Schmidt C; Teich N
Expert Rev Gastroenterol Hepatol; 2016; 10(2):165-75. PubMed ID: 26588993
[TBL] [Abstract][Full Text] [Related]
9. Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins?
D'Amico F; Danese S; Peyrin-Biroulet L
Expert Opin Biol Ther; 2020 Apr; 20(4):353-361. PubMed ID: 31951748
[No Abstract] [Full Text] [Related]
10. Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence.
Scribano ML
World J Gastroenterol; 2018 Jun; 24(23):2457-2467. PubMed ID: 29930467
[TBL] [Abstract][Full Text] [Related]
11. Vedolizumab for the treatment of ulcerative colitis.
Shahidi N; Bressler B; Panaccione R
Expert Opin Biol Ther; 2016; 16(1):129-35. PubMed ID: 26567768
[TBL] [Abstract][Full Text] [Related]
12. Dissecting Common and Unique Effects of Anti-α4β7 and Anti-Tumor Necrosis Factor Treatment in Ulcerative Colitis.
Veny M; Garrido-Trigo A; Corraliza AM; Masamunt MC; Bassolas-Molina H; Esteller M; Arroyes M; Tristán E; Fernández-Clotet A; Ordás I; Ricart E; Esteve M; Panés J; Salas A
J Crohns Colitis; 2021 Mar; 15(3):441-452. PubMed ID: 32926095
[TBL] [Abstract][Full Text] [Related]
13. The safety of biological pharmacotherapy for the treatment of ulcerative colitis.
Fiorino G; Bonovas S; Cicerone C; Allocca M; Furfaro F; Correale C; Danese S
Expert Opin Drug Saf; 2017 Apr; 16(4):437-443. PubMed ID: 28279079
[TBL] [Abstract][Full Text] [Related]
14. Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis.
Dignass AU; Siegmund B; Goertz R; Schneidewind G; Fanter L
Scand J Gastroenterol; 2019 Feb; 54(2):178-187. PubMed ID: 30735443
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of vedolizumab in the treatment of ulcerative colitis.
Domènech E; Gisbert JP
Gastroenterol Hepatol; 2016 Dec; 39(10):677-686. PubMed ID: 26948838
[TBL] [Abstract][Full Text] [Related]
16. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
Lam MC; Bressler B
Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
[TBL] [Abstract][Full Text] [Related]
17. Vedolizumab: an α4β7 integrin inhibitor for inflammatory bowel diseases.
Smith MA; Mohammad RA
Ann Pharmacother; 2014 Dec; 48(12):1629-35. PubMed ID: 25186623
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis.
Jin Y; Lin Y; Lin LJ; Zheng CQ
World J Gastroenterol; 2015 May; 21(20):6352-60. PubMed ID: 26034371
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety of vedolizumab for inflammatory bowel disease.
Loftus EV; Feagan BG; Panaccione R; Colombel JF; Sandborn WJ; Sands BE; Danese S; D'Haens G; Rubin DT; Shafran I; Parfionovas A; Rogers R; Lirio RA; Vermeire S
Aliment Pharmacol Ther; 2020 Oct; 52(8):1353-1365. PubMed ID: 32876349
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age.
Yajnik V; Khan N; Dubinsky M; Axler J; James A; Abhyankar B; Lasch K
Adv Ther; 2017 Feb; 34(2):542-559. PubMed ID: 28070861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
